Anzeige
Mehr »
Montag, 03.08.2026 - Börsentäglich über 12.000 News
Heavy Rare Earths: Der nächste Megatrend?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A422GY | ISIN: US72941H8060 | Ticker-Symbol: XMP1
München
31.07.26 | 20:52
3,450 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CERENOME INC Chart 1 Jahr
5-Tage-Chart
CERENOME INC 5-Tage-Chart

Aktuelle News zur CERENOME Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPlus Therapeutics Inc.: Cerenome Launches as an Integrated CNS Oncology Company402HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective...
► Artikel lesen
21.07.CNSide Diagnostics signs coverage deal with Medical Mutual13
21.07.Plus Therapeutics Inc.: Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer334HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed...
► Artikel lesen
16.07.Plus Therapeutics partners with GTC on CSF diagnostic platform15
16.07.Plus Therapeutics Inc.: Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide CSF Assay Platform299HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company") and Genomic Testing Cooperative, LCA ("GTC") today announced a collaboration...
► Artikel lesen
14.07.Plus Therapeutics Inc.: Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring224HOUSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), today highlighted the recent update to the National Comprehensive Cancer Network (NCCN)...
► Artikel lesen
01.07.Plus Therapeutics rebrands as Cerenome as it deepens AI strategy3
30.06.Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY3
CERENOME Aktie jetzt für 0€ handeln
30.06.Plus Therapeutics Inc.: Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding406Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide commercial progress HOUSTON, June 30...
► Artikel lesen
25.06.Plus Therapeutics wins Elevance Health coverage deal3
25.06.CNSide signs coverage deal with Elevance Health for 45.4M4
25.06.Plus Therapeutics Inc.: Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer4
23.06.Plus Therapeutics Inc.: Plus Therapeutics to Provide Business Update Call on June 30, 20264
18.06.PLUS THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans13
05.06.PLUS THERAPEUTICS, INC. - 8-K, Current Report6
04.06.CNSide Diagnostics receives laboratory accreditation from CAP1
04.06.Plus Therapeutics Inc.: Plus Therapeutics Announces CAP Accreditation of CNSide Diagnostics Clinical Laboratory7
26.05.Plus Therapeutics Inc.: Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases19
19.05.Plus Therapeutics partners with Ephemeral on AI platform5
19.05.Plus Therapeutics kooperiert mit Ephemeral bei KI-Plattform für die Onkologie5
Weiter >>
83 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1